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 Ischemia remains the most significant 
cause of acute kidney injury (AKI), an 
affl  iction associated with high degrees of 
morbidity and mortality. As has been 
widely documented, there are very few 
eff ective treatments for AKI. 1 Th erefore, 
an understanding of the pathophysiologi-
cal processes promoting or preventing 
injury is critical to the potential develop-
ment of novel therapeutics. AKI due to 
ischemia results in impaired renal blood 
fl ow that contributes to the reduction in 
glomerular fi ltration rate, promotes renal 
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 A GAP in our knowledge 
of vascular signaling in 
acute kidney injury 
 David P.  Basile 1 
 Injury resulting from ischemia – reperfusion injury is a multifactorial 
process involving compromised function in both the tubular and the 
vascular compartments. Multiple vasoactive compounds have been 
implicated in the profound vasoconstriction that occurs in response to 
ischemia – reperfusion injury, and many of these factors signal through 
common G protein-coupled receptors. The report by Siedlecki  et al. 
highlights the important roles of RGS4, a GTPase-accelerating protein 
(GAP), in the regulation of vascular tone in the setting of acute 
kidney injury. 
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medullary hypoxia, and exacerbates 
cellular injury. 2 The reduction in renal 
blood fl ow is multifactorial but, at least in 
the initiating stages, is due to enhanced 
renal vascular tone. 
 Th e increase in renal vascular resistance 
in AKI has been proposed to be due to 
activation of the tubuloglomerular feed-
back mechanism and the production of 
vasoactive compounds that promote con-
striction. 2,3 Factors such as norepine-
phrine, angiotensin II, endothelin-1, 
thromboxane A 2 , and adenosine have 
been implicated in vasoconstriction in the 
setting of renal injury. A central role for 
vascular smooth muscle is supported by 
studies in which Ca   +   +   channel blockers 
or antagonists of the aforementioned vaso-
constrictors improve renal perfusion 
and minimize renal injury following 
renal ischemia – reperfusion. 2 – 4 These 
approaches seldom result in complete pro-
tection from injury and may not be entirely 
specifi c to the vascular smooth muscle. 
 It is noteworthy that most vasoconstric-
tors are proposed to mediate ischemic 
AKI signaling through G protein-coupled 
receptors (GPCR), representing a com-
mon regulatory pathway toward vasocon-
striction. GPCRs activate hetero trimeric 
G-protein complexes comprising G  and 
G   subunits. Agonist activation of a 
GPCR initiates the exchange of guanosine 
diphosphate (GDP) for guanosine tri-
phosphate (GTP) on a bound G  , thereby 
stimulating the protein to initiate a down-
stream signaling cascade. 5 Th e duration 
of the signaling event is determined by the 
lifetime of GTP bound to the G  subunit, 
which, in turn, is dictated by the intrinsic 
GTPase activity of the G  . However, the 
intrinsic GTPase of G  proteins can be 
modulated by a family of proteins known 
as regulators of G-protein signaling 
(RGSs), which are GTPase-accelerating 
proteins (GAPs). 5 RGS proteins increase 
the intrinsic rate of GTP hydrolysis by 
the G  , which accounts for the relatively 
fast GTPase activity that occurs  in vivo 
relative to the much longer half-life of 
GTP bound to purified G   in vitro . 5 
The activity of RGS would increase 
GTP hydrolysis and attenuate receptor 
signaling, whereas inhibition of RGS 
would slow GTPase activity and prolong 
GPCR signaling. 
 In mammals, there are more than 20 
known RGS proteins that interact with 
limited selectivity with most G  sub-
types. 5 Of these, both RGS2 and RGS4 are 
of potential interest in vascular and renal 
physiology, as they may partner with the 
G  subtype G  q (Gq / 11), which signals 
angiotensin II, endothelin, vasopressin, 
and thromboxane A 2 . 6 Th e potential role 
of Gq modulation by RGS proteins in 
renal function is not yet clear. Siedlecki 
 et al. 7 (this issue) have investigated the 
potential role of RGS4 activity in the 
pathogenesis of AKI. RGS4 expression 
and localization in the kidney are diffi  cult 
to detect. Th e study now reported by Sie-
dlecki  et al. 7 demonstrates that the  RGS4 
promoter drives expression of a reporter 
transgene almost exclusively in the micro-
vascular smooth muscle in the kidney. 
Although renal expression of RGS4 is 
commentar y
234   Kidney International (2011) 80 
fairly low, its removal in  RGS4  −  /  −     trans-
genic mice has profound functional impli-
cations within the kidney. Kidneys from 
 RGS4   −  /  −   mice show enhan ced and pro-
longed vasoconstriction and inositol-1,4,5-
trisphosphate gene ration in response to 
endothelin-1 infusion using an isolated per-
fusion prepa ration; thus the eff ect of  RGS4 
knockout on vascular tone appears to be 
intrinsic to the kidney and not secondary 
to neural or humoral cues. Th is may trans-
late to the enhanced vascular sensitivity in 
response to injurious stimuli, as  RGS4   −  /  −  
mice showed persistent reductions in renal 
blood fl ow relative to wild-type control ani-
mals following reperfusion using a warm-
ischemia or a cold-transplant injury model. 
As hypoxia during reperfusion is thought 
to promote further cell injury, it is notewor-
thy that  RGS4   −  /  −   animals manifested more 
signifi cant parenchymal injury and death 
than corresponding wild-type controls. 7 
 Is it possible to increase RGS4 activity 
and demonstrate protective eff ects of this 
pathway? Indeed, these investigators took 
advantage of the normal degradation 
pathway of RGS4 by administering the 
proteosomal inhibitor MG-132; this treat-
ment effectively increased renal RGS4 
expression, which attenuated the AKI in 
wild-type animals, but had no eff ect in 
 RGS4   −  /  −   mice. 7 
 Th e current results of Siedlecki  et al. 7 
suggest that RGS4 acts by attenuating vas-
cular Gq signaling and provides a buff er 
against vasoconstriction following a severe 
injurious stimulus ( Figure 1 ). Previous 
work by these investigators demonstrated 
that RGS4 knockout mice have enhanced 
renal vasoconstriction in response to 
cyclosporin A stimulation. 8 
 RGS4 knockout mice are normotensive 
and express no other obvious cardiovas-
cular defects. 8 In contrast, RGS2-defi cient 
mice have hypertension along with abnor-
mal vascular contraction and relaxation 
responses. 6 Recently, it was shown that 
transplantation of kidneys from RGS2 
knockout mice was sufficient to drive 
hypertension in wild-type recipients. 
Conversely, RGS2 knockout mice did 
not develop hypertension following 
transplantation with wild-type kidneys. 
Therefore, it is becoming evident that 
both RGS4 and RGS2 play important 
roles in the maintenance of renal hemo-
dynamic stability. 9 
 Th e new study by Siedlecki  et al. 7 raises 
a number of questions regarding the 
potential relevance of RGS in renal patho-
physiology. For example, how might RGS 
expression levels be regulated to infl uence 
physiological responses? As described by 
Siedlecki  et al. , 7 proteosomal degradation 
represents an important regulatory path-
way for many of the RGS proteins, includ-
ing RGS4 and RGS2. In a recent study, 
 RGS2 alleles, which show increased tar-
geting to the proteosomal degradation 
pathway (and, by implication, enhanced 
Gq signaling), were associated in genetic 
studies with a hypertensive cohort of 
patients. 10 Interestingly, there are elevated 
levels of RGS2 and blunted angiotensin II 
responses in peripheral blood mono-
nuclear cells in patients with Gitelman ’ s 
syndrome, a condition associated with 
hypotension and excessive sodium loss. 11 
Allelic diff erences in the  RGS4 gene have 
thus far not been studied in the context 
of cardiovascular disorders. Given 
that genetic factors infl uencing reactive 
oxygen species have been shown to alter 
the course of AKI, 12 it is reasonable to 
speculate that allelic diff erences in  RGS4 
may alter the severity of AKI. 
 A related question is whether RGS4 
expression can be manipulated such that 
therapies may take advantage of its protec-
tive eff ects. In smooth muscle cells derived 
from rabbit colon, RGS4 expression is 
increased by interleukin-1  , via the activ-
ity of the mRNA-stabilizing protein 
HuR. 13 HuR expression is enhanced in the 
postischemic kidney and may represent an 
adaptive or recovery response, although 
its localization in the vasculature has not 
been explored. 14 It is tempting to speculate 
that factors associated with precondition-
ing may infl uence vascular responses by 
aff ecting smooth muscle signaling. How-
ever, no formal investigation on RGS4 in 
preconditioning has been published, and 
little is currently known regarding the 
factors that may promote RGS4 activity in 
vascular smooth muscle cells. 
 Finally, pharmacological agents may be 
identifi ed with potential RGS4 mimetic 
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 Figure 1  |  Potential role of RGS4 in  protecting against vasoconstriction in response to renal 
injury. Vasoconstrictors modulate their activity within smooth muscle cells via G protein-coupled 
receptors (GPCRs) that activate G  q (Gq), resulting in phospholipase C  (PLC  )-stimulated 
inositol-1,4,5-trisphosphate (IP 3 ) release and leading to Ca 
  +   +   channel-dependent vasoconstriction 
(blue arrows). The activity of the Gq is dependent on the conversion of guanosine triphosphate 
(GTP) to guanosine diphosphate (GDP) with subsequent trimer formation with G  and G  
subunits, which turns off Gq signaling. RGS4 is expressed in renal microvessels and is known 
to enhance GTPase activity; under normal physiological conditions (orange arrow), RGS4 
hastens Gq-mediated GTP-to-GDP conversion, reducing Gq signaling in response to agonist, 
and thus acting as a buffer against severe stimulation. GAP, GTPase-accelerating protein; GFR, 
glomerular filtration rate. 
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 Clinicians recognize that serum creatinine 
oft en increases in response to the adminis-
tration of medications that block the renin – 
angiotensin system. Th is is oft en a source 
of concern, despite the fact that small-scale 
studies in patients with kidney disease indi-
cate that the magnitude of the initial fall of 
estimated glomerular fi ltration rate (GFR) 
is inversely proportional to the long-term 
slope of GFR decline, 1 and systematic 
reviews demonstrate that a rise in serum 
creatinine of up to 30 % above baseline 
activity and may improve renal vascular 
function. For example, BMS-192364 
and BMS-195270 reduce urinary bladder 
contraction and exert RGS-agonist prop-
erties by increasing the action of GAPs 
on Gq proteins. 15 However, this particular 
class of compounds seems eff ective for 
bladder smooth muscle but not vascular 
smooth muscle. Moreover, RGS4 agonists 
may have unintended consequences in 
vascular function; for example, RGS4 in 
endothelial cells attenuates nitric oxide 
activity and inhibits vascular endothelial 
growth factor (VEGF)-induced angion-
genesis, 16 factors that would probably 
exacerbate renal injury processes. 
 Regardless, the elegant study of  Siedlecki 
 et al. 7 has illuminated an important 
new area in the study of renal vascular 
regulation in which multiple vasoactive 
factors are potentially integrated at the 
subcellular level. RGS proteins represent 
an exciting new target by which renal 
hemodynamics may be physiologically 
fi ne-tuned, and the activity of these may 
be impaired in conditions associated with 
renal vascular abnormalities. 
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 Acute fall in glomerular filtration 
rate with renin – angiotensin 
system inhibition: a biomeasure 
of therapeutic success? 
 Matthew R.  Weir 1 
 Glomerular filtration rate (GFR) acutely declines with the introduction of 
renin – angiotensin system inhibition. This response is functional, not 
anatomical, and varies with volume status. The reduction in GFR with 
renin – angiotensin system inhibition may serve as a biomeasure of 
future therapeutic benefit. 
 Kidney International (2011)  80, 235 – 237.  doi: 10.1038/ki.2011.132 
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levels is of no clinical concern as long as 
serum electrolytes remain within normal 
limits. 2 Moreover, clinical studies demon-
strate that any change in renal function or 
serum electrolytes is immediately revers-
ible with cessation of the medication. 3 
Clinical trial data also demonstrate that 
medications that block the renin – angio-
tensin system attenuate the rate of pro-
gression of kidney disease and improve 
survival in patients with diabetes, and 
that patients with higher serum creatinine 
levels derive greater cardiovascular bene fi t 
and greater reduction of the risk of 
renal progression with renin – angiotensin 
system inhibition. 4 – 7  
 Th e new contribution of Holtkamp and 
colleagues 8 (this issue) is very important. 
Not only do their results echo those of a 
smaller study that the same investigators 
